Veristat expands into North Carolina research homeland

North Carolina

Massachusetts-based CRO Veristat is looking to align itself with some of the world’s biggest CROs in the research services homeland of North Carolina.

The company said that it will continue its “accelerated growth and geographic expansion” with the opening of the office in Raleigh-Durham, NC, by fall of this year.

The company will follow in the footsteps of INC Research ($INCR) and Quintiles ($Q), among many other major research companies, who have set up shop in the U.S. R&D services hub.  

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Veristat already has a number of North American-based offices in Southborough, MA; Cambridge, MA; San Bruno, CA; and Montreal, Canada, as well as its European office in Glasgow, U.K.

The new NC office will support the company’s recent growth by providing local support to its clients in the area, the company said. Last month, the CRO bought the U.K.-based cancer research org Spero Oncology for an undisclosed fee, bolstering its own cancer offering and European footprint.

“Veristat has hired many talented clinical research professionals in North Carolina,” said Patrick Flanagan, CEO of Veristat, in a statement.

“The Raleigh-Durham area has a population that includes a very experienced and professional CRO community. We have hired and will continue to hire very talented individuals to grow our team of biometrics and clinical operations professionals. Having a local office will facilitate the expansion of our team and allow us to better serve the clinical development needs of our clients.”

- check out the release

Related Articles:
North Carolina’s controversial transgender bill irks CROs
Veristat buys U.K.’s Spero Oncology in European push

Read more on

Suggested Articles

The EMA and FDA will need traditional clinical trial hurdles removed if governments want the inoculations as quickly as possible.

A new survey by Clinical Research IO has found that nearly one-quarter of polled trial investigators have stopped enrolling new patients.

CRO Charles River Laboratories has signed up to use a preclinical digital pathology software-as-a-service platform from Deciphex.